Catecholamine-induced cardiomyopathy associated with neuroblastoma is rarely reported. We report a case of catecholamineinduced cardiomyopathy associated with neuroblastoma in a 33-month-old female that was treated with extracorporeal membrane oxygenation (ECMO). She was tentatively diagnosed with acute myocarditis and presented with hypertension. Because of rapid patient deterioration despite pharmacological treatments, ECMO was applied. ECMO can be helpful in cases of catecholamine-induced cardiomyopathy associated with neuroblastoma.
Her initial blood pressure (BP) was 150/115 mmHg, heart rate (HR) was 170 beats per minute (bpm), and the arterial oxygen saturation as measured with pulse oximetry was 98%. On physical examination, heart sounds were regular without murmur and her abdomen was soft and flat without any palpable mass.
A plain chest radiograph showed cardiomegaly (cardiothoracic ratio 57%) and perihilar patchy infiltrates in the right lung field; an electrocardiogram showed sinus tachycardia. Polymerase chain reaction tests were performed to identify any virus present in nasopharyngeal secretions; the results were negative. Administration of 12 mg intravenous furosemide cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. and an infusion of dobutamine at the rate of 10 μg/kg/min did not reduce her dyspnea. After two days of hospitalization, the patient developed excessive sweating with cyanosis. An electrocardiogram revealed sinus tachycardia with ST elevation, and a plain chest radiograph showed increased cardiomegaly (cardiothoracic ratio 59%) and bilateral alveolar infiltrates (Fig. 1) . Laboratory studies revealed abnormalities in the cardiac enzymes (creatine kinase-MB 9.4 ng/mL, troponin I 1.45 ng/mL, pro-brain natriuretic peptide 
ECMO. Mitral valvuloplasty was additionally performed to
treat severe mitral regurgitation due to ruptured chordae tendineae, which had been found on intraoperative transesophageal echocardiography (Fig. 2) . During the postoperative period, the patient was hypertensive at 120-200 mmHg/50-115 mmHg and tachycardic at 110-150 bpm. Therefore, sodium nitroprusside was infused intravenously at a rate of 0.5 to 1.0 μg/kg/min, along with nicardipine at 1 to 2 μg/kg/ min. Propranolol was also intermittently administered for hypertension and tachycardia during the postoperative period. However, the patient's BP was not easily controlled.
For further evaluation of perioperative hypertension, thoracic and abdominal computed tomography angiography was performed, revealing a 4-cm heterogeneous mass in the left kidney, consistent with neuroblastoma (Fig. 3) . Urine and plasma catecholamine analysis also showed significant increases in the excretion of urine and plasma catecholamines and their metabolites ( Table 1 ). The patient was transferred to another pediatric hospital for further evaluation and management, where she underwent nephrectomy and recovered without any complications.
Discussion
Catecholamine-induced cardiomyopathy associated with neuroblastoma has rarely been reported; however, it is a well-known complication caused by pheochromocytoma.
Most cases have been of dilated cardiomyopathy presenting with heart failure. Some patients presented with hypertension and all showed increased urine catecholamine levels.
Therefore, hypertension itself is not an essential factor of cardiomyopathy, but the result of excessive catecholamine release, which leads to cardiac muscle damage and downregulation of adrenergic receptors. [1] [2] [3] [4] [5] The pathogenesis of cardiomyopathy is multifactorial. Catecholamine-induced vasoconstriction or coronary vasospasm, free radical generation, chronic tachycardiomyopathy secondary to a hyperadrenergic state, -adrenergic receptor downregulation, and promotion of calcium influx into sarcolemma are the primary etiogenetic factors. [6] Cardiomyopathy in all above-mentioned cases improved after treatment of the neuroblastoma.
The management of catecholamine-induced cardiomyopathy is mainly by using inotropic and antihypertensive agents, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics. Antihypertensive agents should be chosen with proper understanding of heart failure and the severity of outflow obstruction. [4] In our patient, because cardiomyopathy deteriorated despite pharmacological management, ECMO was implemented as a bridge to recovery, which provided time to restore heart functions without vital organ damage. Till now, there has been one case of catastrophic catecholamine-induced cardiomyopathy associated with pheochromocytoma, rescued by performing ECMO. [7] An interesting point in our case was the finding of ruptured mitral chordae tendineae when she was weaned from ECMO. Shiraishi et al [8] reported that acute heart failure due to rupture of mitral chordate tendineae in infants is attributed to diverse causes. While the most common underlying disease is Kawasaki disease (10 cases among 95), there is no case of catecholamine-induced cardiomyopathy. It is possible that the placing of the vent catheter into the left ventricle was the reason for rupture of the mitral chordae tendineae.
Catecholamine-induced cardiomyopathy associated with neuroblastoma is rare but life-threatening, and care should be taken to ensure that it is managed with the proper pharmacological agents. Moreover, ECMO could be the treatment of choice as a bridge to recovery if the patient deteriorates rapidly despite pharmacological treatments. To that end, a pediatrician should thoroughly evaluate the etiology 
